<DOC>
	<DOCNO>NCT01664975</DOCNO>
	<brief_summary>The purpose study evaluate efficacy safety GDPT regiment ( gemcitabine，cisplatin , Prednisone , Thalidomide ) patient Peripheral T-cell lymphoma .</brief_summary>
	<brief_title>Treatment Peripheral T-cell Lymphoma</brief_title>
	<detailed_description>Patients Peripheral T-cell lymphoma usually bad prognosis . These patient treat successfully conventional chemotherapy CHOP . The investigator proceed trial evaluate efficacy safety combination chemotherapy regiment GDPT regiment ( gemcitabine，cisplatin , Prednisone , Thalidomide ) patient Peripheral T-cell lymphoma .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Age range 1470 year old ; ECOG performance status 02 ; Estimated survival time &gt; 3 month Histological confirm Peripheral T cell lymphoma None chemotherapy radiotherapy previously use None chemotherapy contraindication : hemoglobin ≥ 90 g/dl , neutrophil ≥ 1.5×109/L , platelet ≥ 100×109/L , ALT AST ≤ 2×ULN , serum bilirubin ≤ 1.5×ULN , serum creatine ≤ 1.5×upper limitation normal ( ULN ) , Serum Albumin ≥ 30g/L , serum plasminogen normal ( Inclusion Criteria 1,3,6 group ) At least one measurable lesion None serious disease , cardiopulmonary function normal Pregnancy test woman reproductive age must negative Patients could follow None relative treatment include traditional Chinese medicine , immunotherapy , biotherapy except antibone metastasis therapy symptomatic treatment . volunteer sign informed consent . Disagreement blood sample collection Patients allergic drug regimen metabolic disorder Pregnant lactate woman Serious medical illness likely interfere participation Serious infection Primitive secondary tumor central nervous system Chemotherapy radiotherapy contraindication The evidence CNS metastasis History peripheral nervous disorder dysphrenia patient participate clinical trial patient take antitumor drug patient estimate unsuitable investigato</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Peripheral T-cell lymphoma ; chemotherapy ;</keyword>
	<keyword>RR ; PFS ; OS</keyword>
</DOC>